The prognostic significance of hematological parameters in women with uterine serous papillary carcinoma (USPC)

被引:12
作者
Younes, Grace [1 ]
Segev, Yakir [1 ]
Begal, Julia [1 ]
Auslender, Ron [1 ]
Goldberg, Yael [1 ]
Amit, Amnon [2 ]
Lavie, Ofer [1 ]
机构
[1] Techn Univ, Rappaport Fac Med, Carmel Med Ctr, Div Gynecol Oncol,Dept Obstet & Gynecol, Haifa, Israel
[2] Techn Univ, Rappaport Fac Med, Rambam Med Ctr, Div Gynecol Oncol,Dept Obstet & Gynecol, Haifa, Israel
关键词
Uterine papillary serous carcinoma; Thrombocytosis; Leukocytosis; Neutrophilia; COLONY-STIMULATING FACTOR; PRETREATMENT SERUM HEMOGLOBIN; PREOPERATIVE LEUKOCYTOSIS; LEUKEMOID REACTION; PLATELET COUNT; THROMBOCYTOSIS; CANCER; CHEMOTHERAPY; SURVIVAL; GRANULOCYTE;
D O I
10.1016/j.ejogrb.2016.01.043
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: Preoperative hematologic parameters: thrombocytosis, leukocytosis and anemia have been demonstrated to be independent poor prognostic factors in ovarian and endometrial cancers. However, little is known about their relation to uterine serous papillary carcinoma (USPC). We evaluated several preoperative hematologic parameters and their association with clinicopathologic features, disease progression and overall survival in USPC patients. Study design: This was a retrospective cohort study reviewing charts of all patients with a histologic pure USPC at two gynecologic oncology centers from January 2000 through July 2012. All patients had comprehensive hematologic tests prior to primary surgical treatment and were exposed to the same adjuvant treatment protocol. Results: The study included 56 patients, mean age at diagnosis 69.4 +/- 15. Six (11%) had platelet count above 400000 10(6)/L, of them four (66%) were dead at the end of follow up (HR = 1.4, p = 0.48; CI 95% 0.5-4.3). The mean hemoglobin level was 12.3 g/dl, fibrinogen 437.5 mg/dL and lymphocytes 2013/mu L. None of these parameters was significantly associated with 5 year survival. Leukocyte and neutrophil levels were adversely associated with survival. Of 15 patients with leukocytosis >10000/mu L, 67% were dead at the end of follow up (HR = 3.98, p = 0.003; CI 95% 1.6-9.8). Of the 27 with neutrophils above 65%, 14(52%) were dead at the end of follow up (HR = 3.1; p = 0.015; CI 95% 1.2-7.8). Conclusions: In patients with USPC, leukocytosis and neutrophilia are associated with aggressive tumor biology, and may predict a lower 5 year survival. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:16 / 20
页数:5
相关论文
共 45 条
  • [1] ARNOLETTI JP, 1995, CANCER, V76, P998, DOI 10.1002/1097-0142(19950915)76:6<998::AID-CNCR2820760613>3.0.CO
  • [2] 2-0
  • [3] ASANO S, 1977, BLOOD, V49, P845
  • [4] Atacag T, 2012, EUR J GYNAECOL ONCOL, V33, P517
  • [5] ABSOLUTE GRANULOCYTE, LYMPHOCYTE, AND MONOCYTE COUNTS - USEFUL DETERMINANTS OF PROGNOSIS FOR PATIENTS WITH METASTATIC CANCER OF THE STOMACH
    BRUCKNER, HW
    LAVIN, PT
    STORCH, JA
    LIVSTONE, EM
    PLAXE, SC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 247 (07): : 1004 - 1006
  • [6] Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer
    Chen, Ming-Huang
    Chang, Peter Mu-Hsin
    Chen, Po-Min
    Tzeng, Cheng-Hwai
    Chu, Pen-Yuan
    Chang, Shyue-Yih
    Yang, Muh-Hwa
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (12) : 1783 - 1790
  • [7] The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium
    Dabrow, MB
    Francesco, MR
    McBrearty, FX
    Caradonna, S
    [J]. GYNECOLOGIC ONCOLOGY, 1998, 71 (01) : 29 - 37
  • [8] Platelet Effects on Ovarian Cancer
    Davis, Ashley N.
    Afshar-Kharghan, Vahid
    Sood, Anil K.
    [J]. SEMINARS IN ONCOLOGY, 2014, 41 (03) : 378 - 384
  • [9] Platelet Count After Chemotherapy is a Predictor for Outcome for Ovarian Cancer Patients
    Eggemann, H.
    Ehricke, J.
    Ignatov, T.
    Fettke, F.
    Semczuk, A.
    Costa, S. D.
    Ignatov, A.
    [J]. CANCER INVESTIGATION, 2015, 33 (05) : 193 - 196
  • [10] Gadducci A, 2003, EUR J GYNAECOL ONCOL, V24, P405